Septerna (SEPN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on June 17, 2025, with shareholders able to vote and submit questions online.
Shareholders will vote on electing two Class I directors and ratifying Ernst & Young LLP as the independent auditor for 2025.
Proxy materials are distributed primarily via the Internet to reduce costs and environmental impact, with printed copies available upon request.
Only stockholders of record as of April 21, 2025, are entitled to vote at the meeting.
Voting matters and shareholder proposals
Shareholders will elect two Class I directors for three-year terms and ratify the appointment of Ernst & Young LLP as auditor.
The board recommends voting FOR both director nominees and the auditor ratification.
Shareholders may submit proposals for the 2026 meeting by December 30, 2025, and must follow advance notice procedures for other business.
Board of directors and corporate governance
The board is divided into three classes with staggered three-year terms; current nominees are Abraham Bassan and Alan Ezekowitz.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independent members.
The chairman and CEO roles are separated to enhance governance and oversight.
Board diversity and independence are emphasized, with most directors meeting Nasdaq and SEC independence standards.
Latest events from Septerna
- Rapidly advancing oral GPCR therapies with strong pipeline and Novo Nordisk partnership.SEPN
Corporate presentation16 Mar 2026 - Pipeline advances and improved financials set stage for clinical milestones in 2026.SEPN
Q4 20259 Mar 2026 - SEP-631 advances to phase II in CSU after robust phase I results; SEP-479 enters clinical trials.SEPN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - SEP-631 showed strong Phase 1 safety and efficacy, advancing to Phase 2 urticaria trials in 2026.SEPN
Study result2 Mar 2026 - Lead GPCR programs advance toward clinical milestones, supported by strong platform and partnerships.SEPN
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Advancing oral GPCR-targeted therapies with strong clinical pipeline and Novo Nordisk partnership.SEPN
Corporate presentation13 Jan 2026 - GPCR platform drives rapid pipeline growth, with SEP786 and SEP631 clinical data expected in 2025.SEPN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - SEP-479, a next-gen oral PTH1R agonist, advances with improved efficacy and safety profile.SEPN
Cantor Global Healthcare Conference 20255 Jan 2026 - Advancing GPCR-targeted therapies, with SEP-479 and SEP-631 nearing major clinical milestones.SEPN
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025